Clinical variables such as age, parity, lactation, and pathological markers (tumor type, grade, and hormonal receptors) were assessed.Recent literature reports HER2/neu overexpression in 9%-40% of breast cancers, most commonly around 20% [16,19-21]. This evidence concerns the gene ERBB2 and breast cancer.